Cover Image
市場調查報告書

PharmaPoint:A、B型血友病基因重組型製劑補充療法 - 全球醫藥品市場預測與市場分析

PharmaPoint: Hemophilia A and B Recombinant Factor Replacement Therapy - Global Drug Forecast and Market Analysis to 2024

出版商 GlobalData 商品編碼 354677
出版日期 內容資訊 英文 333 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:A、B型血友病基因重組型製劑補充療法 - 全球醫藥品市場預測與市場分析 PharmaPoint: Hemophilia A and B Recombinant Factor Replacement Therapy - Global Drug Forecast and Market Analysis to 2024
出版日期: 2015年12月11日 內容資訊: 英文 333 Pages
簡介

A、B型血友病基因重組型製劑市場2014年的銷售額,主要7個國家和阿根廷是53億8千萬美元。2024年預計達到62億5千萬美元,以1.52%的年複合成長率 (CAGR) 成長。

本報告提供A、B型血友病基因重組型製劑補充療法市場相關調查分析,疾病的概要與指南,競爭情形,主要藥物的詳細資訊 (產品說明、安全性、有效性) 、SWOT分析,銷售額預測,影響分析 (趨勢,推動因素、阻礙因素) 等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因、病理生理學
    • 病因
    • 病理生理學
    • 預後、QOL
  • 症狀
    • A、B型血友病
    • 抑制劑

第4章 流行病學

  • 疾病的背景
  • 危險因素和合併症
  • 全球趨勢
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法
  • 流行病學預測:A型血友病
    • 確診的患者數
    • 確診的患者數:各年齡
    • 確診的患者數:性別
    • 確診的盛行率:年齡調整
  • 流行病學預測:B型血友病
    • 確診的患者數
    • 確診的患者數:各年齡
    • 確診的患者數:性別
    • 確診的盛行率:年齡調整
  • 流行病學預測:A、B型血友病
    • 確診的患者數
    • 確診的患者數:性別
  • 討論
    • 流行病學的趨勢相關考察
    • 分析的限制
    • 分析的優勢

第5章 疾病的管理

  • 治療概要
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 阿根廷

第6章 競爭評估

  • 概要
  • 策略性競爭企業的評估
  • 產品簡介

第7章 機會及未滿足需求

  • 概要
  • 機會分析
  • 未滿足需求的差距分析

第8章 開發平台評估

  • 概要
  • 後期開發的候補藥
  • 初期開發中的有潛力的藥劑

第9章 現在、未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • Baxalta
    • Bayer
    • Biogen
    • CSL Behring
    • Novo Nordisk
    • Pfizer

第10章 市場預測

  • 全球市場
  • 美國
  • EU5個國家
  • 日本
  • 阿根廷

第11章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC116PIDR

Congenital hemophilia A and B are bleeding disorders that are caused by genetic X-linked deficiencies in the blood clotting Factors VIII and IX, respectively. Hemophilia manifests as mild, moderate, or severe inability to form clots, depending upon the endogenous levels of circulating factor in an individual patient. The mainstay of treatment for hemophilia is to replace the missing FVIII or FIX, produced using plasma-derived or recombinant methods. Some patients develop inhibitors to FVIII or FIX treatment and need a bypassing agent, such as FVIIa, to resolve bleeds. Patients of hemophilia A or B often require lifelong treatment to prevent and control bleeding episodes, and this therefore represents a lucrative sales opportunity.

GlobalData estimates the 2014 sales for recombinant hemophilia A and B markets at approximately $5.38 billion across the 7MM+A covered in this report. The market is expected to reach $6.25 billion in 2024 at a CAGR of 1.52%. This growth will be mainly driven by an increasing use of routine prophylaxis and a greater use of recombinant products in place of plasma-derived therapies.

The hemophilia recombinant treatment pipeline is strong, and crowded with multiple long-acting recombinant clotting factors; however, GlobalData expects a lack of initiative for hemophilia A patients to switch to long-acting rFVIII, and a limited scope for premium pricing for new agents, restraining the market growth. Overall, Baxalta is expected to remain as the market leader in the hemophilia space throughout the forecast period, dominating the market with its current gold standard therapy for hemophilia A, Advate, supported by the launch its of pegylated rFVIII, Adynovate.

Highlights

Key Questions Answered

  • What will be the impact of the new long-acting rFVIII and rFIX products in the hemophilia market sales? Led by Biogen's Eloctate and Alprolix, moderate and high rates of adoption of the long-acting rFVIII and rFIX therapies, respectively, are expected.
  • With the growing importance of long-acting Factors, what are the strategies of the companies that have short-acting assets to remain competitive? What are the other approaches that new entrants employ?
  • Prevention of inhibitor formation remains as a major unmet need in the hemophilia space. What are the other unmet needs and opportunities in the hemophilia market?

Key Findings

  • One of the main drivers of the expansion of the hemophilia recombinant market will be the increasing use of routine prophylaxis in pediatric and adult hemophilia A and B patients. Prophylactic regimens have demonstrated improvements in the prevention of bleeding episodes and joint damage. In the 7MM, routine prophylaxis is the standard of care for severe hemophilia patients.
  • The high cost of rFVIII and rFIX therapies is a significant barrier to market growth. Scope for premium pricing for new entrants in the hemophilia A and B market is limited. GlobalData believes that Biogen has set an upper limit to the price of long-acting rFVIII and rFIX products with its competitive pricing strategy for Eloctate and Alprolix.
  • Companies are focusing on the development of therapies that can further reduce the dosing frequency required for prophylaxis. Strategies to prevent inhibitor formation are also sought. Early-stage pipeline products that employ monoclonal antibodies, RNA interference, and gene therapies appear to be highly promising, and represent a huge threat, if they are approved, for the existing treatment options.

Scope

  • Overview of hemophilia, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  • Annualized hemophilia recombinant therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in six patient segments (including on-demand, prophylactic, and inhibitor), forecast from 2014 to 2024.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the hemophilia recombinant therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for different lines of therapy. The most promising candidate in Phase III development is profiled.
  • Analysis of the current and future market competition in the global hemophilia recombinant therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global hemophilia recombinant therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global hemophilia recombinant therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis and Quality of Life
  • 3.2. Symptoms
    • 3.2.1. Hemophilia A and B
    • 3.2.2. Inhibitors

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Sources Not Used
    • 4.4.3. Forecast Assumptions and Methods
  • 4.5. Epidemiological Forecast for Hemophilia A(2014-2024)
    • 4.5.1. Diagnosed Prevalent Cases of Hemophilia A
    • 4.5.2. Diagnosed Prevalent Cases of Hemophilia A by Age
    • 4.5.3. Diagnosed Prevalent Cases of Hemophilia A by Sex
    • 4.5.4. Age-Standardized Diagnosed Prevalence of Hemophilia A
  • 4.6. Epidemiological Forecast for Hemophilia B(2014-2024)
    • 4.6.1. Diagnosed Prevalent Cases of Hemophilia B
    • 4.6.2. Diagnosed Prevalent Cases of Hemophilia B by Age
    • 4.6.3. Diagnosed Prevalent Cases of Hemophilia B by Sex
    • 4.6.4. Age-Standardized Diagnosed Prevalence of Hemophilia B
  • 4.7. Epidemiological Forecast for Hemophilia A and Hemophilia B(2014-2024)
    • 4.7.1. Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
    • 4.7.2. Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Sex
  • 4.8. Discussion
    • 4.8.1. Conclusions on Epidemiological Trends
    • 4.8.2. Limitations of the Analysis
    • 4.8.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Treatment Overview
    • 5.1.1. Hemophilia A and B Diagnosis
    • 5.1.2. Hemophilia A and B Treatment
    • 5.1.3. Diagnosis of Inhibitors
    • 5.1.4. Treatment of Inhibitors
  • 5.2. US
    • 5.2.1. Clinical Practice
  • 5.3. France
    • 5.3.1. Clinical Practice
  • 5.4. Germany
    • 5.4.1. Clinical Practice
  • 5.5. Italy
    • 5.5.1. Clinical Practice
  • 5.6. Spain
    • 5.6.1. Clinical Practice
  • 5.7. UK
    • 5.7.1. Clinical Practice
  • 5.8. Japan
    • 5.8.1. Clinical Practice
  • 5.9. Argentina
    • 5.9.1. Clinical Practice

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Strategic Competitive Assessment
  • 6.3. Product Profiles - Hemophilia A
    • 6.3.1. Advate(Octocog Alfa)
    • 6.3.2. Kogenate FS/Helixate FS(Octocog Alfa)
    • 6.3.3. Xyntha/ReFacto AF(Moroctocog Alfa)
    • 6.3.4. Recombinate(Octocog Alfa)
    • 6.3.5. Eloctate(Efmoroctocog Alfa)
    • 6.3.6. NovoEight(Turoctocog Alfa)
    • 6.3.7. Nuwiq(Simoctocog Alfa)
  • 6.4. Product Profiles - Hemophilia B
    • 6.4.1. BeneFIX(Nonacog Alfa)
    • 6.4.2. Alprolix(Eftrenonacog Alfa)
    • 6.4.3. Rixubis(Nonacog Gamma)
    • 6.4.4. IXinity(Trenonacog Alfa)
  • 6.5. Product Profiles - Hemophilia A and B with Inhibitors
    • 6.5.1. NovoSeven RT(Eptacog Alfa)

7. Opportunity and Unmet Need

  • 7.1. Overview
  • 7.2. Opportunity Analysis
    • 7.2.1. Longer-Lasting Recombinant Factors
    • 7.2.2. Lower-Cost Recombinant Replacement Therapies
    • 7.2.3. Lower Risk of Inhibitor Formation in Previously Untreated Patients
    • 7.2.4. More Convenient Drug Administration
  • 7.3. Unmet Needs Gap Analysis
    • 7.3.1. Long-Acting FVIII Replacement Therapies
    • 7.3.2. Gene Therapy Treatments for Hemophilia A and B

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Late-Stage Development Candidates - Hemophilia A
    • 8.2.1. Kovaltry(Octocog Alfa; BAY 81-8973)
    • 8.2.2. Adynovate(BAX-855)
    • 8.2.3. BAY 94-9027(Damoctocog Alfa Pegol)
    • 8.2.4. N8-GP(Turoctocog Alfa Pegol)
    • 8.2.5. CSL-627(rFVIII-SC)
    • 8.2.6. GreenGene F(Beroctocog Alfa; GC1101C)
  • 8.3. Late-Stage Development Candidates - Hemophilia B
    • 8.3.1. CSL-654(rIX-FP; Albutrepenonacog Alfa)
    • 8.3.2. N9-GP(NN-7999; Nonacog Beta Pegol)
  • 8.4. Late-Stage Development Candidates - Hemophilia A and B Bypassing Agents(Patients with Inhibitors)
    • 8.4.1. BAX-817(rFVIIa BI)
    • 8.4.2. LR-769(rhFVIIa)
    • 8.4.3. CSL-689(rVIIa-FP)
  • 8.5. Promising Drugs in Early-Stage Development
    • 8.5.1. Alternative Coagulation Promoters
    • 8.5.2. Gene Therapies

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Baxalta
    • 9.3.2. Bayer
    • 9.3.3. Biogen
    • 9.3.4. CSL Behring
    • 9.3.5. Novo Nordisk
    • 9.3.6. Pfizer

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Market
  • 10.2. US
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. 5EU
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers - France
    • 10.3.4. Drivers and Barriers - Germany
    • 10.3.5. Drivers and Barriers - Italy
    • 10.3.6. Drivers and Barriers - Spain
    • 10.3.7. Drivers and Barriers - UK
  • 10.4. Japan
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers
  • 10.5. Argentina
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed Hemophilia Patients
    • 11.4.2. Percent Drug-Treated Patients
    • 11.4.3. Drugs Included in Each Therapeutic Class
    • 11.4.4. Launch Dates
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. Individual Drug Assumptions
    • 11.4.7. Pricing of Pipeline Agents
  • 11.5. Primary Research - KOLs Interviewed for this Report
  • 11.6. Primary Research - Prescriber Survey
  • 11.7. Real-World Data
  • 11.8. About the Authors
    • 11.8.1. Analyst
    • 11.8.2. Therapy Area Director
    • 11.8.3. Epidemiologists
    • 11.8.4. Global Head of Healthcare
  • 11.9. About GlobalData
  • 11.10. Disclaimer

List of Tables

  • Table 1: Symptoms of Hemophilia A and B
  • Table 2: Relationship of Bleeding Severity with Clotting Factor Level
  • Table 3: Hemophilia - Risk Factors and Comorbidities
  • Table 4: 9MM, Diagnosed Prevalence of Hemophilia A (per 100,000 Population), Both Sexes, All Ages, 2004-2013
  • Table 5: 9MM, Diagnosed Prevalence of Hemophilia B (per 100,000 Population), Both Sexes, All Ages, 2004-2013
  • Table 6: 9MM, Sources and Diagnosed Prevalence Data for Hemophilia A and B
  • Table 7: 9MM, Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, 2014-2024
  • Table 8: 9MM, Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, by Age, N, Row (%), 2014
  • Table 9: 9MM, Diagnosed Prevalent Cases of Hemophilia A, by Sex, All Ages, N, Row (%), 2014
  • Table 10: 9MM, Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, N, 2014-2024
  • Table 11: 9MM, Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, by Age, N, Row (%), 2014
  • Table 12: 9MM, Diagnosed Prevalent Cases of Hemophilia B, by Sex, All Ages, N, Row (%), 2014
  • Table 13: 9MM, Diagnosed Prevalent Cases of Hemophilia, Both Sexes, All Ages, N, 2014-2024
  • Table 14: 9MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, by Sex, All Ages, N, Row (%), 2014
  • Table 15: Most Prescribed Hemophilia A and B Drugs in the Global Markets, 2015
  • Table 16: Country Profile - US, 2014
  • Table 17: Country Profile - France, 2014
  • Table 18: Country Profile - Germany, 2014
  • Table 19: Country Profile - Italy, 2014
  • Table 20: Country Profile - Spain, 2014
  • Table 21: Country Profile - UK, 2014
  • Table 22: Country Profile - Japan, 2014
  • Table 23: Country Profile - Argentina, 2014
  • Table 24: Leading Recombinant Replacement Therapies for Hemophilia A and B and Patients with Inhibitors, 2015
  • Table 25: Product Profile - Advate
  • Table 26: Advate SWOT Analysis, 2015
  • Table 27: Global Sales Forecast ($m) for Advate, 2014-2024
  • Table 28: Product Profile - Kogenate FS/Helixate FS
  • Table 29: Kogenate FS/Helixate FS SWOT Analysis, 2015
  • Table 30: Global Sales Forecast ($m) for Kogenate FS/Kogenate Bayer, 2014-2024
  • Table 31: Global Sales Forecast ($m) for Helixate FS/Helixate NexGen, 2014-2024
  • Table 32: Product Profile - Xyntha/ReFacto AF
  • Table 33: Xyntha/ReFacto AF SWOT Analysis, 2015
  • Table 34: Global Sales Forecast ($m) for Xyntha/ReFacto AF, 2014-2024
  • Table 35: Product Profile - Recombinate
  • Table 36: Recombinate SWOT Analysis, 2015
  • Table 37: Global Sales Forecast ($m) for Recombinate, 2014-2024
  • Table 38: Product Profile - Eloctate
  • Table 39: Eloctate SWOT Analysis, 2015
  • Table 40: Global Sales Forecast ($m) for Eloctate, 2014-2024
  • Table 41: Product Profile - NovoEight
  • Table 42: NovoEight SWOT Analysis, 2015
  • Table 43: Global Sales Forecast ($m) for NovoEight, 2014-2024
  • Table 44: Product Profile - Nuwiq
  • Table 45: Nuwiq SWOT Analysis, 2015
  • Table 46: Global Sales Forecast ($m) for Nuwiq, 2014-2024
  • Table 47: Product Profile - BeneFIX
  • Table 48: BeneFIX SWOT Analysis, 2015
  • Table 49: Global Sales Forecast ($m) for BeneFIX, 2014-2024
  • Table 50: Product Profile - Alprolix
  • Table 51: Alprolix SWOT Analysis, 2015
  • Table 52: Global Sales Forecast ($m) for Alprolix, 2014-2024
  • Table 53: Product Profile - Rixubis
  • Table 54: Rixubis SWOT Analysis, 2015
  • Table 55: Global Sales Forecast ($m) for Rixubis, 2014-2024
  • Table 56: Product Profile - IXinity
  • Table 57: IXinity SWOT Analysis, 2015
  • Table 58: Global Sales Forecast ($m) for IXinity, 2014-2024
  • Table 59: Product Profile - NovoSeven RT
  • Table 60: NovoSeven RT SWOT Analysis, 2015
  • Table 61: Global Sales Forecast ($m) for NovoSeven RT, 2014-2024
  • Table 62: Overall Unmet Needs - Current Level of Attainment
  • Table 63: Hemophilia A - Phase III Pipeline, 2015
  • Table 64: Product Profile - Kovaltry
  • Table 65: Kovaltry SWOT Analysis, 2015
  • Table 66: Global Sales Forecast ($m) for Kovaltry, 2014-2024
  • Table 67: Product Profile - Adynovate
  • Table 68: Adynovate SWOT Analysis, 2015
  • Table 69: Global Sales Forecast ($m) for Adynovate, 2014-2024
  • Table 70: Product Profile - BAY 94-9027
  • Table 71: Efficacy of BAY 94-9027 in the PROTECT VIII study
  • Table 72: BAY 94-9027 SWOT Analysis, 2015
  • Table 73: Global Sales Forecast ($m) for BAY 94-9027, 2014-2024
  • Table 74: Product Profile - N8-GP
  • Table 75: N8-GP SWOT Analysis, 2015
  • Table 76: Global Sales Forecast ($m) for N8-GP, 2014-2024
  • Table 77: Product Profile - CSL-627
  • Table 78: CSL-627 SWOT Analysis, 2015
  • Table 79: Global Sales Forecast ($m) for CSL-627, 2014-2024
  • Table 80: Product Profile - GreenGene F
  • Table 81: GreenGene F SWOT Analysis, 2015
  • Table 82: Global Sales Forecast ($m) for GreenGene F, 2014-2024
  • Table 83: Hemophilia B - Phase III Pipeline, 2015
  • Table 84: Product Profile - CSL-654
  • Table 85: CSL-654 SWOT Analysis, 2015
  • Table 86: Global Sales Forecast ($m) for CSL-654, 2014-2024
  • Table 87: Product Profile - N9-GP
  • Table 88: N9-GP SWOT Analysis, 2015
  • Table 89: Global Sales Forecast ($m) for N9-GP, 2014-2024
  • Table 90: Hemophilia A and B with Inhibitors - Phase III Pipeline, 2015
  • Table 91: Product Profile - BAX-817
  • Table 92: BAX-817 SWOT Analysis, 2015
  • Table 93: Global Sales Forecast ($m) for BAX-817, 2014-2024
  • Table 94: Product Profile - LR-769
  • Table 95: LR-769 SWOT Analysis, 2015
  • Table 96: Global Sales Forecast ($m) for LR-769, 2014-2024
  • Table 97: Product Profile - CSL-689
  • Table 98: CSL-689 SWOT Analysis, 2015
  • Table 99: Global Sales Forecast ($m) for CSL-689, 2014-2024
  • Table 100: Alternative Coagulation Promoters - Early-Stage Pipeline, 2015
  • Table 101: Hemophilia A and B Gene Therapies - Early-Stage Pipeline, 2015
  • Table 102: Key Companies in the Hemophilia A and B Recombinant Therapies Market, 2014-2024
  • Table 103: Baxalta's Hemophilia Recombinant Portfolio Assessment, 2015
  • Table 104: Baxalta SWOT Analysis, 2015
  • Table 105: Bayer's Hemophilia Recombinant Portfolio Assessment, 2015
  • Table 106: Bayer SWOT Analysis, 2015
  • Table 107: Biogen's Hemophilia Recombinant Portfolio Assessment, 2015
  • Table 108: Biogen SWOT Analysis, 2015
  • Table 109: CSL Behring's Hemophilia Recombinant Portfolio Assessment, 2015
  • Table 110: CSL Behring SWOT Analysis, 2015
  • Table 111: Novo Nordisk's Hemophilia Recombinant Portfolio Assessment, 2015
  • Table 112: Novo Nordisk SWOT Analysis, 2015
  • Table 113: Pfizer's Hemophilia Recombinant Portfolio Assessment, 2015
  • Table 114: Pfizer SWOT Analysis, 2015
  • Table 115: Sales Forecast ($m) for Hemophilia A and B Recombinant Therapies in the 7MM+A, 2014-2024
  • Table 116: Global Hemophilia A and B Market - Drivers and Barriers, 2014-2024
  • Table 117: Sales Forecast ($m) for Hemophilia A and B Recombinant Therapies in the US, 2014-2024
  • Table 118: Key Events Impacting Sales for Hemophilia A and B in the US, 2014-2024
  • Table 119: US Hemophilia A and B Market - Drivers and Barriers, 2014-2024
  • Table 120: Sales Forecasts ($m) for Hemophilia A and B Recombinant Therapies in the 5EU, 2014-2024
  • Table 121: Key Events Impacting Sales for Hemophilia A and B Recombinant Therapies in the 5EU, 2014-2024
  • Table 122: French Hemophilia A and B Recombinant Therapies Market - Drivers and Barriers, 2014-2024
  • Table 123: German Hemophilia A and B Recombinant Therapies Market - Drivers and Barriers, 2014-2024
  • Table 124: Italian Hemophilia A and B Recombinant Therapies Market - Drivers and Barriers, 2014-2024
  • Table 125: Spanish Hemophilia A and B Recombinant Therapies Market - Drivers and Barriers, 2014-2024
  • Table 126: UK Hemophilia A and B Recombinant Therapies Market - Drivers and Barriers, 2014-2024
  • Table 127: Sales Forecast ($m) for Hemophilia A and B Recombinant Therapies in Japan, 2014-2024
  • Table 128: Key Events Impacting Sales for Hemophilia A and B in Japan, 2014-2024
  • Table 129: Japanese Hemophilia A and B Market - Drivers and Barriers, 2014-2024
  • Table 130: Sales Forecast ($m) for Hemophilia A and B Recombinant Therapies in Argentina, 2014-2024
  • Table 131: Key Events Impacting Sales for Hemophilia A and B in Argentina, 2014-2024
  • Table 132: Argentine Hemophilia A and B Market - Drivers and Barriers, 2014-2024
  • Table 133: Key Launch Dates
  • Table 134: Physicians Surveyed

List of Figures

  • Figure 1: 9MM, Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, 2014-2024
  • Figure 2: 9MM, Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, by Age, N, 2014
  • Figure 3: 9MM, Diagnosed Prevalent Cases of Hemophilia A, by Sex, All Ages, N, 2014
  • Figure 4: 9MM, Age-Standardized Diagnosed Prevalence of Hemophilia A (per 100,000 Population), by Sex, 2014
  • Figure 5: 9MM, Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, N, 2014-2024
  • Figure 6: 9MM, Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, by Age, N, 2014
  • Figure 7: 9MM, Diagnosed Prevalent Cases of Hemophilia B, by Sex, All Ages, N, 2014
  • Figure 8: 9MM, Age-Standardized Prevalence of Diagnosed Hemophilia B (per 100,000 Population), by Sex, 2014
  • Figure 9: 9MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, 2014-2024
  • Figure 10: 9MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, by Sex, All Ages, N, 2014
  • Figure 11: Competitive Assessment of Late-Stage Pipeline Agents in Hemophilia A, 2014-2024
  • Figure 12: Competitive Assessment of Late-Stage Pipeline Agents in Hemophilia B, 2014-2024
  • Figure 13: Competitive Assessment of Late-Stage Pipeline Agents for Hemophilia A and B Patients with Inhibitors, 2014-2024
  • Figure 14: Company Portfolio Analysis in Hemophilia A and B, 2014-2024
  • Figure 15: Global Sales for Hemophilia A and B Recombinant Therapies by Region, 2014-2024
  • Figure 16: Sales for Hemophilia A and B recombinant therapies in the US by Drug Class, 2014-2024
  • Figure 17: Sales for Hemophilia A and B Recombinant Therapies in the 5EU by Drug Class, 2014-2024
  • Figure 18: Sales for Hemophilia A and B Recombinant Therapies in Japan by Drug Class, 2014-2024
  • Figure 19: Sales for Hemophilia A and B Recombinant Therapies in Argentina by Drug Class, 2014-2024
Back to Top